Atea Pharmaceuticals, Inc. (AVIR) |
|
3.395 -0.025 (-0.73%)
|
03-22 14:50 |
|
Open: |
3.44 |
Pre. Close: |
3.42 |
|
High:
|
3.49 |
Low:
|
3.31 |
|
Volume:
|
511,667 |
Market Cap:
|
283(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:15:39 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.48 One year: 4.97 |
| Support: |
Support1: 3.15 Support2: 2.62 |
| Resistance: |
Resistance1: 3.83 Resistance2: 4.26 |
| Pivot: |
3.48  |
| Moving Average: |
MA(5): 3.54  MA(20): 3.5
MA(100): 4.49 MA(250): 6.02 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 39.8 %D(3): 56.7 |
| RSI: |
RSI(14): 37 |
| 52-week: |
High: 9.78 Low: 3.15 |
| Average Vol(K): |
3-Month: 496 (K) 10-Days: 958 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVIR ] has closed above bottom band by 27.9%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.54 - 3.56 |
3.56 - 3.58 |
|
Low:
|
3.32 - 3.34 |
3.34 - 3.36 |
|
Close:
|
3.38 - 3.42 |
3.42 - 3.45 |
|
Company Description |
|
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. |
Headline News |
Wed, 22 Mar 2023
Atea Pharmaceuticals Inc. (AVIR) Stock Records -25.81% Quarterly ... - The News Heater
Tue, 21 Mar 2023
A significant driver of top-line growth: Atea Pharmaceuticals Inc. (AVIR) - SETE News
Fri, 17 Mar 2023
Atea Pharmaceuticals Inc (AVIR) Stock: What Does the Chart Say Friday? - InvestorsObserver
Wed, 08 Mar 2023
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research - Yahoo Finance
Tue, 28 Feb 2023
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 ... - GlobeNewswire
Tue, 21 Feb 2023
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
83 (M) |
| Shares Float |
70 (M) |
|
% Held by Insiders
|
9.1 (%) |
|
% Held by Institutions
|
70.5 (%) |
|
Shares Short
|
1,800 (K) |
|
Shares Short P.Month
|
1,480 (K) |
Stock Financials |
|
EPS
|
-1.55 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.69 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-11.4 |
|
Return on Equity (ttm)
|
-17.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.99 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.57 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-121 (M) |
|
Levered Free Cash Flow
|
-82 (M) |
Stock Valuations |
|
PE Ratio
|
-2.17 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.43 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-2.32 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
